Skip to main content

Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis

Journal of Neuro-Oncology volume 104, pages 545–551 (2011)Cite this article

Abstract

The development of better diagnostic tools and therapeutic modalities has increased the incidence of central nervous system (CNS) metastasis in malignant tumor patients. Hydrocephalus can result from CNS metastasis and frustrate cancer treatment. The authors sought to investigate the outcomes and the roles of ventriculoperitoneal shunts (VPS) in patients with CNS metastasis. The medical records of 50 consecutive patients who underwent VPS for hydrocephalus related to CNS metastasis were analyzed retrospectively. Data included features of primary malignancies, CNS involvement, clinical course and surgical outcome. Median patient age was 55.0 years (range 25–77), and 30 female and 20 male patients were included in the study. At the time of VPS, 10 patients had parenchymal metastases only and 40 patients had leptomeningeal seeding (LMS). Symptom improvement was observed postoperatively in 40 patients (80%), mean Karnofsky performance status (KPS) scale change was from 37.8 to 46.0, and median survival from VPS was 3.0 months (2 days to 54 months). A ventricular opening pressure of >30 cmH2O (HR 6.44, 95% CI 1.26–32.9, P = 0.02) and further cancer treatment after VPS (HR 0.17, 95% CI 0.07–0.42, P < 0.0001) were found to be independent risk factors of poorer and better survival, respectively. Hydrocephalus in CNS metastasis requiring VPS is commonly associated with LMS. VPS is an effective palliative measure and an adequate cancer treatment after VPS may provide the best means of improving survival.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Kehrli P (1999) Epidemiology of brain metastases. Neurochirurgie 45:357–363

    PubMed  CAS  Google Scholar 

  2. Herrlinger U, Forschler H, Kuker W, Meyermann R, Bamberg M, Dichgans J, Weller M (2004) Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci 223:167–178

    PubMed  Article  Google Scholar 

  3. Omuro AM, Lallana EC, Bilsky MH, DeAngelis LM (2005) Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 64:1625–1627

    PubMed  Article  Google Scholar 

  4. Taillibert S, Hildebrand J (2006) Treatment of central nervous system metastases: parenchymal, epidural, and leptomeningeal. Curr Opin Oncol 18:637–643

    PubMed  Article  Google Scholar 

  5. Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M (2010) Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol (in press)

  6. Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K, Delattre JY (2005) Leptomeningeal metastases from solid malignancy: a review. J Neurooncol 75:85–99

    PubMed  Article  Google Scholar 

  7. Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P, Egorin MJ (1998) High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 16:1561–1567

    PubMed  CAS  Google Scholar 

  8. Lassman AB, Abrey LE, Shah GD, Panageas KS, Begemann M, Malkin MG, Raizer JJ (2006) Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 78:255–260

    PubMed  Article  CAS  Google Scholar 

  9. Berger MS, Baumeister B, Geyer JR, Milstein J, Kanev PM, LeRoux PD (1991) The risks of metastases from shunting in children with primary central nervous system tumors. J Neurosurg 74:872–877

    PubMed  Article  CAS  Google Scholar 

  10. Lobotesis K, UK-I JM, Cross JJ, Gillard JH, Antoun NM (2009) Gliomatosis peritonei associated with a ventriculo-peritoneal shunt. Clin Radiol 64:95–99

    PubMed  Article  CAS  Google Scholar 

  11. Zemack G, Romner B (2000) Seven years of clinical experience with the programmable Codman Hakim valve: a retrospective study of 583 patients. J Neurosurg 92:941–948

    PubMed  Article  CAS  Google Scholar 

  12. Chamberlain MC, Glantz M (2006) Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 66:783, author reply 783

    Google Scholar 

  13. DeAngelis LM, Boutros D (2005) Leptomeningeal metastasis. Cancer Invest 23:145–154

    PubMed  Google Scholar 

  14. Pentheroudakis G, Pavlidis N (2005) Management of leptomeningeal malignancy. Expert Opin Pharmacother 6:1115–1125

    PubMed  Article  CAS  Google Scholar 

  15. Groves MD (2010) New strategies in the management of leptomeningeal metastases. Arch Neurol 67:305–312

    PubMed  Article  Google Scholar 

  16. Chamberlain MC, Kormanik P (1998) Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 55:506–512

    PubMed  Article  CAS  Google Scholar 

  17. Chamberlain MC, Kormanik PR (1997) Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 35:55–64

    PubMed  Article  CAS  Google Scholar 

  18. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O’Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell SB (2001) Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 84:157–163

    PubMed  Article  CAS  Google Scholar 

  19. Kesari S, Batchelor TT (2003) Leptomeningeal metastases. Neurol Clin 21:25–66

    PubMed  Article  Google Scholar 

  20. Barker FG 2nd (2005) Surgical and radiosurgical management of brain metastases. Surg Clin North Am 85:329–345

    PubMed  Article  Google Scholar 

  21. Shapiro WR, Johanson CE, Boogerd W (2009) Treatment modalities for leptomeningeal metastases. Semin Oncol 36:S46–S54

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

    Seung Hoon Lee, Doo Sik Kong, Ho Joon Seol, Do-Hyun Nam & Jung-Il Lee

Authors
  1. Seung Hoon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Doo Sik Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ho Joon Seol
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Do-Hyun Nam
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jung-Il Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jung-Il Lee.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lee, S.H., Kong, D.S., Seol, H.J. et al. Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis. J Neurooncol 104, 545–551 (2011). https://doi.org/10.1007/s11060-010-0512-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-010-0512-2

Keywords

  • Ventriculoperitoneal shunt
  • CNS metastasis
  • Risk factor
  • Survival